Concord Healthcare Grp Co Ltd reported a challenging QQ4 2024 from a profitability and liquidity perspective, with a sharp YoY revenue decline and continued net losses. Revenue for the quarter was CNY 84.66 million, down 65.86% YoY, while gross profit remained negative at CNY -16.37 million, yielding a gross margin of -19.34%. The company posted an operating loss of CNY -108.08 million and a net loss of CNY -130.67 million (EPS -0.18). Despite the negative income statement, some operating metrics reflect structural cost pressures easing versus prior periods, as evidenced by a YoY improvement in gross profit (reported as -19.34% gross margin vs. a deeper negative level in prior periods) and an EBITDA of -50.18 million (margin -0.59%). Free cash flow (FCF) was positive at approximately CNY 80.44 million, driven by capital expenditures and financing activity, even as operating cash flow remained modestly negative (-3.58 million). The balance sheet shows pronounced leverage: total debt of approximately CNY 3.21 billion, net debt around CNY 3.01 billion, and a current ratio of 0.63, indicating tighter liquidity. Cash and cash equivalents stood at roughly CNY 0.205 billion, with additional short-term investments (~CNY 0.133 billion). Management commentary from the earnings call is not available in the provided data, so direct quotes could not be incorporated. The current quarter underscores the need for strategic deleveraging, utilization improvement, and cost control to achieve a sustainable path to profitability amid a growing but competitive Chinese oncology services market.